on SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech Reports Half-Year Liquidity Contract Update
On July 3, 2026, Sartorius Stedim Biotech SA released its half-year liquidity contract statement for the period ending June 30, 2026. As part of the agreement with Kepler Cheuvreux, the liquidity account held 38,829 shares and €6,040,068.12.
During the semester, there were 5,718 buy-side executions totaling 342,335 shares and €60,345,559.44, while the sell-side saw 5,179 executions for 336,472 shares at €59,875,054.42. In comparison, the previous semester ended December 2025, reported 32,966 shares and €6,457,086.94 on the liquidity account.
Implemented under AMF Decision N°2021-01, the liquidity contract remains a standard market practice. Sartorius Stedim Biotech, a key player in biopharmaceuticals, continues to strengthen its global presence through strategic acquisitions, providing robust biotech solutions.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news